Policosanol-Atorvastatina for Ictus

Effects of policosanol and atorvastatin on ischemic stroke recovery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

RPCEC

Registry ID

RPCEC00000167

Enrollment

Registered

2013-09-02

Start date

2013-09-02

Completion date

Unknown

Last updated

2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic stroke

Interventions

Study Group. Policosanol (20 mg). One tablet daily during 3 months, Aspirin (125 mg). One tablet daily during 3 months. Control Group. Atorvastatin (20 mg). One tablet daily during 3 months, Aspirin

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: The sample will be comprised 1.Patients of both sexes 2. Age = 20 years 3. documented history of previous (3 months) TIA or ischemic stroke (diagnosed within 30 days of its appearance) 4. who agree to participate in the study 5. With neurological deficit of Rankin Scale 2 -5 6. Without exclusion criteria.

Exclusion criteria

Exclusion criteria: 1. Neoplasms diagnosed 2. atrial fibrillation 3. diastolic hypertension 4. history of hemorrhagic stroke or subarachnoid hemorrhage 5. documented evidence of cerebral aneruisma, history of myocardial infarction, unstable angina or revascularization in the 6 months prior the study 6. any other special conditions threatening their health and their lives during the study.

Design outcomes

Primary

Measure	Time frame
Neurological deficit (Modified Rankin Scale: 0 No symptoms, 1 Symptoms but able to perform all usual activities, 2 slight disability but able to carry out activities without assistance, 3 moderate disability, requiring some help, but able to walk without assistance, 4 moderately severe disability, 5 = severe disability: bedridden, incontinent, and requires nursing care and constant attention). Measuring time: baseline and after 4, 8 and 12 weeks on treatment.	—

Measure

Time frame

Neurological deficit (Modified Rankin Scale: 0 No symptoms, 1 Symptoms but able to perform all usual activities, 2 slight disability but able to carry out activities without assistance, 3 moderate disability, requiring some help, but able to walk without assistance, 4 moderately severe disability, 5 = severe disability: bedridden, incontinent, and requires nursing care and constant attention). Measuring time: baseline and after 4, 8 and 12 weeks on treatment.

—

Secondary

Measure	Time frame
Blood biochemical parameters Total cholesterol (mmol / L) , Triglycerides (mmol / L), LDL-C (mmol / L), HDL-C (mmol / L)). Measuring time: at baseline and 6 months. PSA test (PSA, ng/mL). Measuring time: at baseline and 6 months.	—

Countries

Cuba

Contacts

Public ContactSarahi Mendoza Castaño

Center of Natural Products, National Center for Scientific Research

sarahi.mendoza@cnic.edu.cu

Outcome results

None listed

Source: RPCEC (via WHO ICTRP) · Data processed: Aug 15, 2026